RGX-314: Initiate pivotal program of subretinal delivery in wet AMD in H2. Start Phase 2 studies of suprachoroidal delivery in wet AMD in H1. File IND in H1 for suprachoroidal delivery in diabetic retinopathy followed by the launch of a Phase 2 study in H2.
RGX-121: Release additional interim data from Phase 1/2 study in MPS II this quarter. Report interim data from cohort 2 mid-year. H2: accelerated approval pathway possible, contingent on analysis interim data.
RGX-501: Release interim data on LDL-C levels from Phase 1/2 study in HoFH in H1.
Hereditary angioedema: Select lead candidate in H1.
RGX-181: IND to be filed in H2 for CLN2 disease.
Zolgensma: Regulatory decision in Europe expected this quarter and in Japan in H1. Novartis is the licensee ($175M in sales through Q3 2019).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.